Current Report · Items 2.02, 9.01 · 8-K

Kura Oncology, Inc.

KURANASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Mar 5, 2026Accepted Mar 5, 2026, 6:35 AM ESTCIK 1422143Accession 0001193125-26-092465

Company context

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Current securities

KURANASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On March 5, 2026, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2025 and providing a corporate update. A copy of this press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Filed exhibits (1)

EX-99.1 (by filename) kura-ex99_1.htm

EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports Fourth Quarter and full year 2025 Financial Results - KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions - - Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients - - Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI - - FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma - - Multiple 2026 clinical data milestones expected across AML and solid tumor programs - - Strong capital position of $667.2 million in cash, cash equivalents and short-term investments, together with $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program to first topline Phase 3 results in KOMET-017 - - Management to host webcast and conference call today at 8:00 a.m. ET - SAN DIEGO, March 5, 2026 - Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cance…

Open exhibit ↗

Free Registration